Hep C Triple Drug Combo Effective Without Interferon or Ribavirin | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Working Human Liver Tissue Created with 3D-Bioprinting

Back to News Homepage
Next

Should Hepatitis C Treatment Include Selenium?

Hep C Triple Drug Combo Effective Without Interferon or Ribavirin

The Editors at Hepatitis Central
May 3, 2013

Print this page

In a small, open-label Phase II Hepatitis C study, an interferon-free and ribavirin-free combination of three direct-acting antivirals led to treatment success rates in the 90th percentile.

Daclatasvir/asunaprevir/NS5B inhibitor effective in treatment-naive HCV patients

April 30, 2013

Treatment-naive patients with chronic hepatitis C experienced high rates of sustained virologic response from a combination of three direct-acting antivirals in a study presented at the International Liver Congress in Amsterdam.

In an open-label phase 2 study, researchers randomly assigned 32 treatment-naive patients with chronic HCV genotype 1 to 60 mg NS5A inhibitor daclatasvir (DCV) once daily, 200 mg protease inhibitor asunaprevir (ASV) twice daily and 75 mg non-nucleoside NS5B inhibitor BMS-791325 twice a day for 24 or 12 weeks (n=16 each). A second cohort was later assigned DCV, ASV and 150 mg BMS-791325 (Bristol-Myers Squibb) for 24 (n=16) or 12 weeks (n=18).

Continue reading this entire article:
http://www.healio.com/hepatology/chronic-hepatitis/news/online/%7B9073D629-ADD8-412C-A8A6-EA7A3A55FC6E%7D/DaclatasvirasunaprevirNS5B-inhibitor-effective-in-treatment-naive-HCV-patients

3 Comments
Share
Share
Previous

Working Human Liver Tissue Created with 3D-Bioprinting

Back to News Homepage
Next

Should Hepatitis C Treatment Include Selenium?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.